Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
15.53
+1.88 (13.77%)
Bozor ochiq: Aug 12, 2026, 11:52 AM EDT
13.65
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:58 PM EDT
Replimune Group, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Amerika Qo'shma Shtatlari va Buyuk Britaniyada saratonni davolash uchun onkolitik immunoterapiyalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning o'ziga xos onkolitik immunoterapiya mahsulot nomzodlari saratonga qarshi immunitet tizimini faollashtirish uchun ishlab chiqilgan va mo'ljallangan. Uning yetakchi mahsulot nomzodi RP1 bo'lib, u GALV-GP R(-) va inson GM-CSF ni turli xil qattiq o'smalar uchun ifodalovchi HSV-1 ning selektiv ravishda ko'payadigan versiyasidir. Kompaniya, shuningdek, CTLA-4 tomonidan keltiriladigan immunitet javobining inhibitsiyasini blokirovka qilish uchun anti-CTLA-4 antitelaga o'xshash oqsilni ifodalovchi RP2; va T-hujayralarni rag'batlantiruvchi immunitetni faollashtiruvchi oqsillarni ifodalovchi RP3 ni ishlab chiqmoqda. Replimune Group, Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Voburn, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Sushil Patel Ph.D. | CEO & Director |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
| Mr. Shawn Glidden J.D. | Senior VP & General Counsel |
| Ms. Carolyn Trott | Senior Vice President of Quality Assurance |
| Ms. Emily Luisa Hill | Chief Financial Officer |
| Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-11 | 8-K/A | tm2622780d1_8k.htm |
| 2026-08-10 | 8-K | tm2622673d1_8k.htm |
| 2026-08-07 | 8-K | tm2622487d1_8k.htm |
| 2026-07-31 | 8-K | tm2621708d1_8k.htm |
| 2026-07-30 | 8-K | tm2621663d1_8k.htm |
| 2026-07-29 | DEFA14A | tm263608d3_defa14a.htm |
| 2026-07-29 | DEF 14A | tm263608-4_def14a.htm |
| 2026-07-24 | S-3/A | tm2620954-1_s3a.htm |
| 2026-07-13 | PRE 14A | tm263608-1_pre14a.htm |
| 2026-06-29 | S-8 | tm2618985d1_s8.htm |